Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.58 |
| ▸ | MAOA | P21397 | 1/20 | 0.51 |
| ▸ | MAOB | P27338 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 9/20 | 0.49 |
| ▸ | CA2 | P00918 | 9/20 | 0.49 |
| ▸ | CA12 | O43570 | 6/20 | 0.49 |
| ▸ | CA9 | Q16790 | 6/20 | 0.49 |
| ▸ | ATM | Q13315 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9945627 | 0.87 | MEN1 (0.69) | MEN1KMT2AGAATDP1MAOA | |
| SCHEMBL12762769 | 0.87 | MEN1 (0.69) | MEN1KMT2AGAATDP1MAOA | |
| SCHEMBL12787794 | 0.87 | MEN1 (0.69) | MEN1KMT2AGAATDP1MAOA | |
| SCHEMBL14871948 | 0.87 | MEN1 (0.59) | MEN1KMT2AGAATDP1MAOA | |
| SCHEMBL25477091 | 0.86 | MEN1 (0.58) | MEN1KMT2AGAATDP1MAOA | |
| SCHEMBL14194795 | 0.86 | MEN1 (0.58) | MEN1KMT2AGAATDP1MAOA | |
| SCHEMBL18251802 | 0.86 | MEN1 (0.67) | MEN1KMT2AGAATDP1MAOA | |
| SCHEMBL19864338 | 0.86 | MEN1 (0.58) | MEN1KMT2AGAATDP1MAOA | |
| SCHEMBL12341542 | 0.85 | MEN1 (0.65) | MEN1KMT2AGAATDP1MAOA | |
| SCHEMBL24664899 | 0.83 | TDP1 (0.67) | MEN1KMT2AGAATDP1MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10695342-B2 | Methods and compositions for preventing opioid abuse | ALBANY MOLECULAR RESEARCH, INC. (US) | 2020-06-30 | — | — | US | disclosed |
| US-20170157116-A1 | METHODS AND COMPOSITIONS FOR PREVENTING OPIOID ABUSE | CURIA BUFFALO R&D, LLC | 2017-06-08 | — | — | US | disclosed |
| US-20150368262-A1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | Prism BioLab Co., Ltd. (JP) | 2015-12-24 | — | — | US | disclosed |
| US-9040531-B2 | Alpha helix mimetics and methods relating thereto | Prism BioLab Co., Ltd. (JP) | 2015-05-26 | — | — | US | disclosed |
| US-20150030626-A1 | IMMUNOMODULATORY CONJUGATES | Ascend Biopharamaceuticals Ltd (AU) | 2015-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150368262-A1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | PLOD3, COL1A1, THPO | MEN1 1064/4885KMT2A 3392/4885GAA 367/4885 |
| US-10695342-B2 | Methods and compositions for preventing opioid abuse | OPRM1, OPRK1, OPRD1 | MEN1 4885/4885KMT2A 3110/4885GAA 470/4885 |
| US-20150030626-A1 | IMMUNOMODULATORY CONJUGATES | CLEC4M, TLR3, CD74 | MEN1 965/4885KMT2A 1035/4885GAA 414/4885 |
| US-20170157116-A1 | METHODS AND COMPOSITIONS FOR PREVENTING OPIOID ABUSE | OPRM1, OPRK1, OPRD1 | MEN1 4885/4885KMT2A 3110/4885GAA 470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.